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Neglected tropical diseases (NTDs) account for a large disease burden in sub-Saharan
Africa. While the general cost-effectiveness of NTD interventions to improve health out-
comes has been assessed, few studies have also accounted for the financial and education
gains of investing in NTD control.
Methods
We built on extended cost-effectiveness analysis (ECEA) methods to assess the health
gains (e.g. infections, disability-adjusted life years or DALYs averted), household financial
gains (out-of-pocket expenditures averted), and education gains (cases of school absentee-
ism averted) for five NTD interventions that the government of Madagascar aims to roll out
nationally. The five NTDs considered were schistosomiasis, lymphatic filariasis, and three
soil-transmitted helminthiases (Ascaris lumbricoides, Trichuris trichiura, and hookworm
infections).
Results
The estimated incremental cost-effectiveness for the roll-out of preventive chemotherapy
for all NTDs jointly was USD125 per DALY averted (95% uncertainty range: 65–231), and
its benefit-cost ratio could vary between 5 and 31. Our analysis estimated that, per dollar
spent, schistosomiasis preventive chemotherapy, in particular, could avert a large number
of infections (176,000 infections averted per $100,000 spent), DALYs (2,000 averted per
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Conclusion
This analysis incorporates financial and education gains into the economic evaluation of
health interventions, and therefore provides information about the efficiency of attainment of
three Sustainable Development Goals (SDGs). Our findings reveal how the national scale-
up of NTD control in Madagascar can help address health (SDG3), economic (SDG1), and
education (SDG4) goals. This study further highlights the potentially large societal benefits
of investing in NTD control in low-resource settings.
Author summary
Neglected tropical diseases (NTDs) cause ill health and disability among the poorest peo-
ple with extensive economic and social effects. Existing cost-effectiveness analyses, how-
ever, have typically focused on the health gains associated with the scale up of preventive
chemotherapy. This misses the key fact that health investments can contribute to gains in
other sectors leading to broader benefits of NTD control. This study determines the value
for money of national NTD control across multiple sectors. We assess the potential health,
financial, and education gains of NTD control in a setting where NTDs are highly
endemic. We build on extended cost-effectiveness analysis methods to examine five inter-
ventions which governments aim to scale up nationally. We find that, per dollar spent,
preventive chemotherapy could avert a substantial number of infections, disability-
adjusted life years or DALYs, and cases of school absenteeism. Our analysis incorporates
broader wealth and education gains into the economic evaluation of health interventions
and therefore provides information about the efficiency of attainment of three Sustainable
Development Goals. This study highlights the potentially large societal benefits of invest-
ing in NTD control.
Introduction
Neglected tropical diseases (NTDs) affect more than 1 billion individuals worldwide [1].
NTDs are typically a consequence of environmental and socioeconomic conditions and cause
ill health and disability among the poorest and most marginalized people [2]. Moreover, the
economic and social effects of NTDs are extensive [2, 3]. NTDs affect household and worker
productivity [4–6] and are associated with substantial loss of work time [7, 8]. Interventions to
control NTDs promise large economic pay-offs outside the health sector in agricultural pro-
ductivity and educational benefits, and have been considered as investments in human capital
and poverty reduction [9]. Given that the existing tools to control NTDs are effective, inexpen-
sive, and the dividends are large, ending these diseases has been suggested as one of the most
cost-effective interventions in population health [1]. As a result, a range of elimination and
control initiatives for individual diseases has emerged, including the London Declaration on
NTDs, inspired by the World Health Organization’s (WHO) 2020 roadmap on NTDs, and the
Sustainable Development Goal (SDG) target 3.3 to end the epidemic of NTDs by 2030 [10].
Health, financial, and education gains of NTD control in Madagascar
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007002 December 27, 2018 2 / 17
study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Competing interests: The authors have declared
that no competing interests exist.
Existing cost-effectiveness analyses of NTD control, however, have typically focused on the
health gains associated with the scale-up of preventive chemotherapy in low-resource settings
[1, 2]. This is surprising given the wide array of economic and social benefits of investing in
NTD control [11]. The first edition of Disease Control Priorities (DCP) already made this point
in 1993, further highlighting the broad impact of worm infections (helminthiases) [12]:
“The principal public health significance of the helminthiases resides, then, not in their effect
on mortality but, rather, in their consequences of impaired growth and development in chil-
dren, chronic disability, and long-term impairment of function. These consequences, com-
bined with the extremely high prevalence of many helminthic infections, suggest aggregate
outcomes for these conditions that are very substantial from the standpoint of both economic
productivity and general welfare.”
The contents of the DCP served as powerful background information for the World Bank’s
World Development Report 1993 [13], the estimation of disability-adjusted life years
(DALYs), the ‘worm wars’ [14, 15], and the recently published third edition of DCP [16].
Furthermore, given limited resources, policymakers dealing with NTDs face difficult deci-
sions often having to balance multiple sectoral goals beyond health. The typical framework
used allocates resources to optimize population health. This approach risks missing the fact
that health investments contribute to gains in other sectors and may lead to underestimating
the broader benefits of NTD control [17]. If NTD control, for instance, contributes to educa-
tional gains, policymakers in the education sector may be willing to contribute to the cost of
NTD control in a co-financing approach between the education and health sectors to achieve
their respective goals jointly [16, 18]. While previous work has documented the extensive ben-
efits of NTD control across the SDG spectrum [13], our study attempts to comprehensively
quantify the extended cost-effectiveness of NTD control across multiple sectors.
To address this objective, we assessed the potential health, financial, and education gains of
national NTD control in Madagascar, where NTDs are highly endemic (see S1 Text in the
Appendix for contextual information). In the spirit of extended cost-effectiveness analysis
(ECEA) methods [19, 20], we examine interventions for five NTDs which the government
aims to scale-up nationally: “lymphatic filariasis” (LF), “schistosomiasis”, and three intestinal
parasites i.e. “soil-transmitted helminthiases” (STH) (Ascaris lumbricoides, Trichuris trichiura,
and hookworm). This study focuses on the cost of scaling up NTD control efforts nationally
and its impact on morbidity and mortality, out-of-pocket (OOP) treatment costs for house-
holds, as well as on educational outcomes. The goal of this study is not to assess the costs and
benefits of NTD elimination in Madagascar; rather we propose a modeling approach and illus-
trate it by assessing the potential costs and benefits of scaling up NTD control.
Methods
Building on ECEA, we developed a modeling approach to examine the health gains (infections
and DALYs averted), household financial gains (reduction in OOP treatment costs), and edu-
cation gains (cases of school absenteeism averted, defined in years of schooling gained) result-
ing from NTD interventions in Madagascar (Table 1). These interventions included
preventive chemotherapy for schistosomiasis, STH, and LF, delivered through school-based
mass drug administration (MDA) [21, 22]. For simplicity, we assumed that these interventions
were incremental to the current status quo with no other interventions taking place before
their rollout. While this may be the case at the national level, in practice a number of interven-
tions have already occurred at subnational levels. For example, the SECALINE program
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(“Sécurité alimentaire et nutrition élargie”–or Expanded Food Security and Nutrition) pro-
vided school-based deworming in two provinces in Madagascar between 1993 and 2003 [23].
Similarly, there might have been programmatic efforts by scientific institutions (e.g. Institut
Pasteur) or non-governmental organizations [22].
Fig 1 displays an analytical framework for our analysis [19]. For each intervention, we esti-
mated: the number of infections and DALYs averted; the reduction in household financial bur-
den associated with seeking care for NTD-related conditions; and the number of cases of
school absenteeism averted (years of schooling gained). These amounts depended on the target
population size, NTD prevalence, intervention coverage and effectiveness, the probability of
developing clinical conditions resulting from NTD infection, healthcare usage, average house-
hold expenditures on NTD treatment, and the education burden assigned to NTD infections.
Despite some services being provided free of charge by the government, around 41% of (total)
health expenditure are financed privately in Madagascar [26]. Therefore, with free preventive
chemotherapy for NTDs, we assumed individuals would still pay on average about 41% of




























Provision of albendazole (400 mg) and
diethylcarbamazine (100 mg)
5–14 years old 6,325,000 0% 72% Ministry of
Health
Notes: All five NTD interventions were delivered through mass drug administration. Coverage is defined as therapeutic coverage of the NTD program. Geographic
coverage would be 100% after the national scale-up of the NTD program. Our analysis does not examine onchocerciasis or trachoma (other NTDs amenable to
preventive chemotherapy) since they are not endemic in Madagascar. Source: Ministry of Health, Madagascar [21, 24, 25].
https://doi.org/10.1371/journal.pntd.0007002.t001
Fig 1. Analytical framework underlying the economic evaluation approach. Analytical structure building on the
extended cost-effectiveness analysis methodology where impact is estimated in four domains: cost to the government;
health gains (i.e., morbidity and mortality due to infections averted); household financial gains (i.e., private out-of-
pocket expenditures averted); and education gains (i.e., increased educational attainment among school-going age
children) [19].
https://doi.org/10.1371/journal.pntd.0007002.g001
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clinical treatment costs for the remaining NTD-related medical issues (e.g., surgical manage-
ment of hydrocele or lymphedema resulting from chronic LF).
We used government reports to estimate the program costs of the interventions analyzed
[21]. Table 2 displays a breakdown of costs of Madagascar’s 2013 NTD program. Program
costs included community mobilization and supervision of staff; whereas all drugs used for the
program were donated by pharmaceutical companies. Using the total cost of the campaign
and the number of individuals targeted, we inferred the unit cost per individual. In sensitivity
analyses, we added drug costs assuming drugs would not be donated by pharmaceutical com-
panies. No other adjustments to the costs data were made. Additional details on Madagascar’s
NTD program are provided in S1 Text in the Appendix.
We selected input parameters for our economic model in two steps. First, we conducted a
narrative literature review of the evidence to identify meaningful estimates for each parameter
(Appendix, S1 Text). Second, when multiple sources were identified for a parameter, we chose
estimates based on source quality and similarity of the context with a Madagascar setting. If
source quality or setting was not a differentiating factor, we opted for the more conservative
estimate. In additional analyses, we varied our input parameters to assess the sensitivity of our
findings to alternative parameter specifications. All parameter inputs used are listed in
Table 3.
We present results for an ‘integrated’ program scenario, where the cost of an NTD cam-
paign targeted to school-going age children covers the roll-out of preventive chemotherapy for
all NTDs (as opposed to modeling all five NTD intervention independently–each with its own
programmatic cost) [27, 28]. Indeed, the Madagascar NTD program was rolled out together to
generate programmatic synergies [21]. Moreover, the same preventive chemotherapy is used
to control multiple NTDs. Albendazole, for instance, is used to control all three STH (ascaria-
sis, trichuriasis, and hookworm disease) as well as LF in areas where LF is co-endemic [21].
Mathematical derivations
We summarize here the mathematical derivations for our key outcomes including: program
costs, the number of infections averted, household OOP treatment expenditures averted, and
cases of school absenteeism averted (in years of educational attainment gained). For the five
NTD interventions (D = schistosomiasis, STH, LF), the program targets school-age children
(5–14 year-olds, Pop5-14). We denote pD the probability of treatment for disease D conditional
on having D; cOOP,D the OOP costs for disease treatment; and cgov,D the government costs for
Table 2. Itemized budget for the neglected tropical disease program in Madagascar (2013 campaign).
Level National (2013 USD) Regions (2013 USD) Districts (2013 USD)
Coordination meetings 18,000 - -
Staff training 32,000 93,000 58,000
Office supplies 13,000 - -
Tools 36,000 - -
Community mobilization 16,000 2,000 203,000
Transport 7,000 - 12,000
Supervision 29,000 6,000 243,000
Evaluation meetings 9,000 11,000 84,000
Total 160,000 112,000 600,000
Notes: The cost of the campaign was 1,938,962,848 Malagasy Ariary (MGA) (2013) and the number of individuals targeted by the campaign was 4,433,902. Source:
Rapport synthétique d’activités et de résultats TMM-PAUSENS 2013 Maladies Tropicales Negligées, Ministère de la Santé Publique, Gouvernement de Madagascar
(2013).
https://doi.org/10.1371/journal.pntd.0007002.t002
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disease treatment. Preventive chemotherapy (PC) has an effectiveness PCeff and the incremen-
tal coverage achieved is Cov.
From the government perspective, the incremental costs of PC would be:
TCPC ¼ ½ðndoses�cprev þ cprogÞ�Pop5  14�; ð1Þ
where ndoses is the number of treatment doses; cprev is the price per dose; and cprog is the cost of
the program per individual. cprev = 0 when drugs are donated by pharmaceutical companies
(we relax this assumption in a sensitivity analysis where we include drug costs), and ndoses = 1
since the campaign included one annual dose.
The number of infections averted is assumed to be:
Prevpost;D ¼ PCeff�Cov�Prevante;D; ð2Þ
where Prevante,D is the number of cases of D among Pop5-14 before program.
The number of cases of school absenteeism averted would be:
Schoolpost;D ¼ PCeff�Cov�Schoolante;D; ð3Þ
where Schoolante,D is the number of cases of school absenteeism associated with NTDs among the
school-going age population Pop5-14 before program (i.e., education burden associated with NTD
infections). As we identified no data on school years lost due to NTD infections in Madagascar,
we used data from a randomized deworming program in primary schools in Kenya to estimate
Schoolante, which found that treatment among children would increase educational attainment by
about 0.15 years in the long run [30], and assumed: Schoolante, D = Pop5-14 � Prevante,D � 0.15.
The amount of household OOP expenditures averted by the program would be Epost = Prevpost
� pS � pD � cOOP,D, where Prevpost is the number of infections averted, pS the probability of develop-
ing clinical symptoms resulting from D, pD the probability of seeking treatment for D (conditional
on having D), and cOOP,D the OOP costs for D treatment.













25% [29] 237,000 [30] 60% [31] 1 [26, 32, 33] 37% [34]
Ascariasis preventive
chemotherapy
26% [29] 247,000 [30] 60% [31] 1 [26, 32, 33] 31% [35]
Hookworm disease preventive
chemotherapy
7% [29] 66,000 [30] 60% [31] 1 [26, 32, 33] 100% [35]
Trichuriasis preventive
chemotherapy
24% [29] 228,000 [30] 60% [31] 1 [26, 32, 33] 13% [35]
Lymphatic filariasis preventive
chemotherapy
3% [29] 28,000 [30] 2% [36] 22 [26, 37] 45% [38]
Notes: Healthcare use is among those who have clinical symptoms. To calculate household out-of-pocket payments (column 4), we assumed that 41% of (total) health
expenditure was financed privately in Madagascar and derived average estimates [26]. We used the effectiveness from mass drug administration campaigns since this
was closest to the planned national roll-out of the NTD program in Madagascar. Conversion rates for Malagasy Ariary (MGA) to United States dollar (USD) were
0.00045 (2013) and 0.00055 (2005) using https://www.xe.com/currencycharts/. Inflation from USD 2005 to USD 2013 was taken into account using https://data.bls.gov/
cgi-bin/cpicalc.pl (1.0 USD 2005 = 1.2 USD 2013).
https://doi.org/10.1371/journal.pntd.0007002.t003
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Benefit-cost ratio
We examined the ratio of the full spectrum of benefits of NTD control in monetary units
divided by the total cost of investing in NTD control. We converted DALYs gained into a
monetary value (USD). We assessed a range of monetary values since there is no formal con-
sensus on how much to spend to avert a DALY in low-resource settings [39, 40]. To assess the
monetary value of education gains, we used data from the Labor Force Surveys of Madagascar
and evidence on the annual rates of return to schooling. The average monthly salary in Mada-
gascar has been estimated at 55,000 Malagasy Ariary (about USD20), or 667,000 Malagasy Ari-
ary (about USD230) per year, whereas the estimated return to one additional year of schooling
has been quantified at 11% (of an individual’s wage) [41]. To capture the present value of long-
run wage benefits associated with preventive chemotherapy, we conservatively assumed wage
benefits over 20 years discounted at 3% per year [42]. We used data on the average wage in
Madagascar (as opposed to the minimum wage) since the labor market is dominated by non-
wage earners (only 11% of the labor force earns a salary) [43]. The average wage is lower than
the minimum wage in the private sector [44].
Subnational analysis
To assess the distributional impact, we examined the subnational variation in the effects of
the program on health, financial, and education gains. Field studies conducted in Madagas-
car between 2015 and 2016 suggest that the prevalence of STH among school-aged children
ranges from 0 to 94% (Appendix, S1 Fig). A similarly large range has been observed for
schistosomiasis, which ranged from 1 to 89% in endemic districts (106 out of 114 districts).
The prevalence of LF ranged from 0 to 58% (in 99/114 districts) [22]. We examined the dif-
ferential impact of rolling out the program using a range of values for prevalence that is rep-
resentative of the distributions seen in Madagascar. Specifically, we used 5%, 25%, 45%,
65%, and 85% as prevalence for the five NTDs. For instance, in the districts Ampanihy,
Beloha, Ihosy and Toliara II in South-Western Madagascar, the prevalence of STH ranges
from 1 to 8%. Conversely, in the districts Mananara Avaratra, Maroantsetra, Toamasina I
and Toamasina II in North-Eastern Madagascar, the prevalence of STH ranges from 77 to
99%. A similarly high prevalence of STH is found along the Eastern coast [22]. We expect
that the combination of high prevalence and focus on smaller geographic areas increases the
cost-effectiveness of NTD control in highly endemic districts. It is likely that national NTD
interventions may ultimately focus on specific “hot spots” where NTDs are highly endemic
using regionally targeted campaigns.
Sensitivity analyses
Univariate and multivariate sensitivity analyses were conducted to explore the sensitivity of
our findings to various parameter assumptions.
Considerable uncertainty exists around NTDs, including prevalence and intensity of infec-
tion and of related conditions, their distributions, effectiveness of MDA to control NTDs, as
well as on the effect of NTD control on economic and social outcomes. In particular, there has
been some degree of controversy around the effect of NTD control on school participation
[14, 15, 45] and previous cost-effectiveness calculations [46]. To acknowledge the uncertainty
around our results, we conducted a probabilistic sensitivity analysis using Monte Carlo simula-
tions (n = 1,000) [47, 48], where we assumed selected distributions for each key input parame-
ter including disease prevalence, treatment effectiveness, the percentage of paid workers in
Madagascar, healthcare costs, and averted years of school absenteeism (school years gained)
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(Appendix, S1 Table). We then extracted 95% uncertainty ranges (UR) capturing the uncer-
tainty in our findings. We used R statistical software version 3.4.3 for all simulations.
We also examined sensitivity to key input parameters, one at a time. First, we assumed that
all drugs were donated by pharmaceutical companies, which may not always be the case, par-
ticularly after 2020 (a number of large manufacturers have pledged to continue large medicinal
donations under the London Declaration for the period 2014–2020) [49]. We therefore tested
alternative input parameters for the drug costs: USD0.080/tablet for schistosomiasis (prazi-
quantel at 2.5 tablets of 600mg per person-year); and USD0.045/tablet (albendazole at 1 tablet
of 400mg per person-year) and USD0.004/tablet (diethylcarbamazine (DEC) at 2 tablets of
100mg per person-year) for STH and LF [50] (Appendix, S2 Table). Second, we used the total
cost of an entire NTD campaign to model each NTD intervention as an independent campaign
with its own programmatic costs to further understand the contribution of each NTD subin-
tervention (as opposed to an ‘integrated’ program scenario).
Our main model assumed that targeted individuals were independent of each other. In
other words, we assumed that infections averted by preventive chemotherapy for LF infection
were unrelated to those infections averted by preventive chemotherapy for STH. In practice,
we may be “double-counting” the benefits of NTD interventions in cases where there is co-
infection with multiple NTDs within the same individual. This may particularly be the case in
contexts where individuals at risk of NTD infection are also those most likely to be co-infected.
We therefore studied a conservative scenario where we assumed a “worst-case” scenario of
100% co-infection. In other words, we assumed that all NTD infections co-occurred within the
same individuals. (No data was available for Madagascar on the prevalence of co-infection
with multiple NTDs within the same individual). To do so, we changed the following input
parameters: we took the highest prevalence among NTDs in our target group and assumed
that only those individuals were potentially infected with any of the other NTDs—in our appli-
cation, the highest prevalence found was 26% among school-age children (ascariasis); and we
used the lowest effectiveness for preventive chemotherapy among NTD interventions since the
prevention of one NTD is insufficient without preventing other NTDs in co-infected individu-
als (13%, for trichuriasis preventive chemotherapy).
Results
The extent of health, financial, and education gains varied substantially across the five NTD
interventions examined (Table 4). The number of infections averted would range from 61,000
(LF) to 439,000 (schistosomiasis). We also present calculations of DALYs averted for each
NTD intervention, using estimates on the number of DALYs caused by each NTD from the
Global Burden of Disease study (2015) [51]. The number of DALYs averted would range from
300 (trichuriasis) to 4,400 (schistosomiasis). The costs were identical for schistosomiasis, STH,
and LF preventive chemotherapy, since drugs were donated by pharmaceutical companies and
we examined an ‘integrated’ scenario, where all interventions were covered by a single pro-
grammatic delivery platform. Substantial uncertainty accompanied the impact on educational
outcomes.
Schistosomiasis and ascariasis preventive chemotherapy were the two interventions that
prevented the highest number of infections per dollar spent, since schistosomiasis chemother-
apy prevented 176,000 infections and ascariasis chemotherapy prevented 153,000 infections
(per $100,000 spent). Schistosomiasis is highly prevalent (25% nationally) among school-age
children and preventive chemotherapy is comparatively effective (at 37%). By contrast, LF pre-
ventive chemotherapy averted the smallest number of infections per dollar spent, since the
prevalence (3% nationally) is comparatively low.
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There was a relatively small reduction in household OOP treatment expenditures. For LF,
the program would reduce OOP expenditures for the clinical management of chronic LF
(lymphedema and hydrocele) by about $11,000 since healthcare services for chronic LF
appeared underutilized in Madagascar (2%) [36]. For schistosomiasis and STH, the program
would reduce OOP expenditures for the clinical management of symptoms related to infection
by about $12,000 (trichuriasis) to $34,000 (schistosomiasis).
We calculated the incremental cost-effectiveness ratio (ICER) for the entire integrated
NTD program by dividing the total program costs by the total number of DALYs averted. The
estimated ICER was USD125 per DALY averted (95% UR: 65–231). After converting health
and education gains into monetary terms, the benefit-cost ratio was estimated at 13 (5–31)
(Table 5). Alternatively, using a monetary value of USD250 per DALY averted, the benefit-
cost ratio would become 7 (1–19). These results represent the benefits and costs of investing in
an ‘integrated’ NTD program, where the cost of an NTD campaign targeted to school-going
age children covers the roll-out of preventive chemotherapy for all five NTDs jointly.
In S3 Table (Appendix), we illustrate the subnational impact by district using a varying
prevalence of all NTDs in the integrated NTD program. As expected, in average-sized districts
(population of 63,000) with an 85% prevalence of all NTDs (i.e. “hot spots”), preventive che-
motherapy would avert a large number of infections, DALYs, and school years lost. In contrast,
in districts with a 5% prevalence, preventive chemotherapy would avert a very small number
of infections, DALYs, and school years lost. These results imply, as expected, strong geographi-
cal variation in the cost-effectiveness of NTD control in Madagascar and the need for region-
ally targeted approaches.
Sensitivity analyses
Our results were generally consistent across sensitivity analyses (Appendix, S4–S6 Tables).
When each NTD intervention was modelled independently with its own programmatic cost
(instead of an ‘integrated’ program), the benefit-cost ratio would range from 1 (for trichuriasis
Table 4. Infections averted, DALYs averted, household out-of-pocket expenditures averted, and cases of school absenteeism averted for each of the five neglected





Household expenditure averted in
2013 USD (uncertainty intervals)
Cases of school absenteeism averted in
school years (uncertainty intervals)
Schistosomiasis preventive
chemotherapy
439,000 4,400 34,000 66,000
279,000–650,000 2,800–6,500 17,000–65,000 4,000–150,000
Ascariasis preventive
chemotherapy
382,000 1,100 30,000 57,000
250,000–581,000 700–1,700 18,000–49,000 4,000–131,000
Hookworm disease
preventive chemotherapy
332,000 1,700 26,000 50,000
157,000–631,000 800–3,400 10,000–57,000 5,000–141,000
Trichuriasis preventive
chemotherapy
148,000 300 12,000 22,000
79,000–268,000 200–600 5,000–25,000 2,000–59,000
Lymphatic filariasis
preventive chemotherapy
61,000 2,400 11,000 9,000
20,000–177,000 900–6,900 3,000–37,000 1,000–36,000
Total 1,362,000 9,900 113,000 204,000
785,000–2,307,000 5,400–19,100 53,000–233,000 16,000–517,000
Notes: The NTD program was considered to be delivered through mass drug administration nationwide. Uncertainty intervals were constructed using upper and lower
bounds for prevalence of NTDs, effectiveness of treatment, DALYs assigned to NTDs, probability of developing NTD-related morbidity and treatment costs in Monte
Carlo simulations (n = 1,000 runs) as explained in the Methods section. DALYs per infection used data from the Global Burden of Disease study 2015 (column 2). Link:
http://ghdx.healthdata.org/gbd-results-tool.
https://doi.org/10.1371/journal.pntd.0007002.t004
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preventive chemotherapy) to 5 (for schistosomiasis preventive chemotherapy). When adding
drug costs to the campaign costs, the benefit-cost ratio would be reduced to about 4 (S5
Table). Taking into account the possibility of co-infection with NTDs within the same individ-
uals (with the conservative 100% overlap), the benefit-cost ratio would be reduced to about 1
(S6 Table).
Discussion
We presented results for a comprehensive economic evaluation of five NTD interventions in
Madagascar. We examined the likely consequences of scale-up of NTD preventive chemother-
apy in averting infections, in addition to the potential household financial and education
gains. This type of analysis distinguishes itself from a traditional cost-effectiveness analysis
because it also includes non-health outcomes, allowing policymakers to make comprehensive
decisions as they choose between alternative funding strategies given limited resources. The
recent institution of the Sustainable Development Goals (SDGs) has garnered increasing atten-
tion to jointly improve health and financial protection (SDG3), reduce poverty (SDG1), and
increase educational attainment (SDG4). Implementation of complementary investments
across sectors is key to reducing and eliminating the NTD burden in the post-2015 develop-
ment agenda [17]. This study examines the broader spectrum of societal benefits of NTD
control.
We modeled each NTD intervention in an ‘integrated’ scenario since NTD interventions
are typically rolled out together to generate programmatic synergies [27, 28], including in
Table 5. Infections averted, DALYs averted, household out-of-pocket expenditures averted, and cases of school absenteeism averted in monetary terms for each of
the five neglected tropical diseases (NTD) interventions in Madagascar.
DALYs averted in
economic burden (1
DALY = 1,000 USD)
DALYs averted in
economic burden (1
DALY = 250 USD)
DALYs averted in
economic burden (1













4,350,000 1,088,000 8,700,000 34,000 1,999,000 6,383,000




1,103,000 276,000 2,206,000 30,000 1,726,000 2,859,000





1,720,000 430,000 3,440,000 26,000 1,514,000 3,260,000





329,000 82,000 658,000 12,000 666,000 1,007,000





2,423,000 606,000 4,846,000 11,000 273,000 2,707,000
862,000–6,901,000 216,000–1,725,000 1,724,000–13,802,000 3,000–37,000 20,000–1,321,000 885,000–
8,259,000
Total 9,925,000 2,482,000 19,850,000 113,000 6,178,000 16,216,000
5,283,000–19,033,000 1,322,000–4,758,000 10,566,000–38,066,000 53,000–233,000 478,000–19,118,000 5,706,000–
38,384,000
Notes: See references for the economic gains associated with one DALY in low-resource settings [39, 40] and additional schooling in Madagascar [41]. We estimated the
monetary gains of schooling using data on wages from the Labor Force Survey of Madagascar (2012) [43]. We counted wage benefits over 20 years discounted at 3% per
year [42]. The total benefits shown in column 6 are based on a monetary value of 1,000 USD per DALY averted [39].
https://doi.org/10.1371/journal.pntd.0007002.t005
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Madagascar [21]. The cost of an NTD campaign targeted to school-going age children there-
fore covered the rollout of preventive chemotherapy for all five NTDs. As expected, the bene-
fit-cost ratio increased substantially with integration. For schistosomiasis, for instance, mass
treatment would have costed USD286 per DALY if rolled out independently of the other four
NTDs. Similarly, NTD interventions may be rolled-out together or in combination with cam-
paigns targeted to other diseases (e.g., immunization or nutrition fortification [2]). The inte-
gration of these services could further reduce costs through economies of scope, and produce
synergistic effects not captured by our model.
Our cost-effectiveness estimates are somewhat higher than those from previous studies [1].
For instance, a study estimated the cost-effectiveness of school-based mass treatment programs
for STH with albendazole or mebendazole at about 2008 USD2-11 per DALY averted [2].
Mass treatment of school-age children in Côte d’Ivoire for STH and schistosomiasis together
costed around 2014 USD118 per DALY averted relative to doing nothing [52]. Even though
the variances around these estimates may still overlap, there may be a number of reasons for
discrepancies between studies [2]. Our modeling, for instance, used effectiveness estimates
from mass treatment campaigns in real-world settings that mirrored the scale-up of NTD con-
trol in Madagascar [34, 35, 38]; in more controlled settings, the efficacy of preventive chemo-
therapy for NTDs may be larger [53, 54]. Other possible reasons for discrepancies include
alternative choices of disability weights [46] or drugs [2], as well as local social and environ-
mental conditions [55]. A recent review on preventive chemotherapy for STH, however, sug-
gests that most studies present results within the range of being highly cost-effective [56], and
NTD interventions seem one of the most cost-effective interventions in public health [1].
Nevertheless, our study presents a number of limitations. First, as with all cost-effectiveness
analyses, our findings rely on the availability and quality of the evidence at hand. Limited
robust evidence was available for the health, financial, and education burden assigned to
NTDs, and the effectiveness of chemotherapy. In our review of the literature, we identified
only limited evidence on the long-run education burden due to NTDs (years of schooling lost)
[30, 57, 58] and we had no data on disease-specific healthcare usage and OOP spending for
four out of five NTDs. Limited data was also available on the incidence of morbidity associated
with chronic NTD infection. A recent systematic review on mass deworming, for instance,
suggested that certainty in the evidence for long-term effects on educational outcomes was
“very low” for STH control [59]. Consistent with the literature, uncertainty intervals around
our estimates for cases of school absenteeism averted (in school years gained) were large.
There is also controversy around the validity of evidence for schooling outcomes [60]. A trial
in Kenya, in which school-based mass treatment with deworming drugs was randomly phased
into schools found protective effects of NTD control on school absenteeism [15, 30]. A recent
replication study, however, found that deworming may be less effective than previously sug-
gested [14, 45, 61]. Second, we did not capture all benefits or costs of NTD control. For
instance, because preventive chemotherapy likely increases labor supply, it could create a fiscal
externality through its impact on tax revenues [62]. Conversely, if deworming allows children
to go back to school and attain a higher level of schooling, the government may need to invest
more in education [30]. Third, the roll-out of NTD control in Madagascar is planned until at
least 2020 [22]. The cost-effectiveness of NTD control will likely decrease over time as NTD
prevalence reduces. Fourth, due to lack of data, we used disease prevalence although it may
not be the best measure to examine interventions addressing macroparasites (as opposed to
viral or bacterial infections) [63–65]. The morbidity associated with NTDs is typically experi-
enced by individuals with high parasitemia, hence the impact of an MDA campaign on mor-
bidity would come from reducing the intensity of infections with high parasitemia (rather
than prevalence). There may also be positive spillover effects for those not treated due to a
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reduction in the level of transmission [15, 30]. In our modeling, we did not take into account
benefits of curing morbidity in individuals who are still infected but with a lower intensity
infection, or possible benefits for those who are not directly treated. These benefits are poten-
tially large as well as long-term (in the case of LF, chronic stages of disease such as hydrocele
may be prevented providing health benefits accruing many years after MDA). Our modeling is
static rather than dynamic, which would have otherwise captured additional synergies includ-
ing transmission and indirect effects, but relied on additional data and assumptions around
NTDs that is not available. Better data about the life history of NTDs is needed, including
intensity of infection, disease severity, and their distributions, as well as transmission and indi-
rect effects [65]. Fifth, the choice of drugs may affect our estimates. The government of Mada-
gascar, for instance, has previously used mebendazole as antihelmintic instead of albendazole
in a number of districts [21], which may have fewer benefits due to its lower efficacy against
hookworm infection [66]. Sixth, the disability weights for the DALYs are intended to be solely
measures of losses of ‘optimal health’, and are not intended to represent losses of economic
productivity or well-being [63, 65]. We used the disability weights in the absence of other data
on productivity losses due to health, similar to the Copenhagen Consensus exercise [39]. Yet,
we focused on school-age children with most long-run economic gains resulting from
increased school attainment, which we took into account. Seventh, our analysis focused on the
most prevalent NTDs in Madagascar but included little case management of NTDs with high
rates of catastrophic expenditure (average OOP treatment expenditures were used). We also
did not examine impoverishment (for example, the number of cases of poverty averted). Lastly,
our economic evaluation approach is only one method for priority setting. Decision-makers
should also consider ethical and political factors, health system constraints, and targeting indi-
viduals at high risk (as opposed to the general population).
Economic evaluations for health policy have typically focused on quantifying the health gains
per given expenditure. Policymakers in low-resource settings, however, face difficult decisions bal-
ancing multiple sectorial goals and require evidence on how to jointly achieve health, economic,
and education objectives. This study attempts to comprehensively model the health, financial, and
education impact of national NTD control in a resource-limited setting, and contributes to our
understanding of how health interventions can affect economic and education aims.
Supporting information
S1 Text. Additional background information and context.
(DOCX)
S1 Table. Base-case values and uncertainty ranges used in the probabilistic sensitivity anal-
ysis.
(DOCX)
S2 Table. Estimated unit cost of drugs (per tablet) for neglected tropical diseases in Mada-
gascar (2012).
(DOCX)
S3 Table. Subnational analysis: Cost-effectiveness of neglected tropical disease control by
different district prevalence categories in Madagascar.
(DOCX)
S4 Table. Benefit-cost analysis of neglected tropical disease (NTD) control in Madagascar.
Each NTD intervention was modelled independently with its own programmatic cost.
(DOCX)
Health, financial, and education gains of NTD control in Madagascar
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007002 December 27, 2018 12 / 17
S5 Table. Univariate sensitivity analysis: Drugs used for preventive chemotherapy for
neglected tropical diseases in Madagascar are not donated for free by pharmaceutical com-
panies.
(DOCX)
S6 Table. Benefit-cost analysis of NTD control in Madagascar using an alternative benefit
scenario: Assuming all infections occur within the same individuals (100% overlap).
(DOCX)
S7 Table. Cure rates of selected drugs for control of NTDs.
(DOCX)
S1 Fig. Prevalence of soil-transmitted helminthiases by district in Madagascar (2016).
(DOCX)
S2 Fig. Distribution of outpatient visits at primary care centers (“Centres de Santé de
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Visualization: Jan-Walter De Neve, Stéphane Verguet.
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Writing – review & editing: Jan-Walter De Neve, Rija L. Andriantavison, Kevin Croke,
Johannes Krisam, Voahirana H. Rajoela, Rary A. Rakotoarivony, Valérie Rambeloson,
Linda Schultz, Jumana Qamruddin, Stéphane Verguet.
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21. Ministère de la Santé Publique, Gouvernement de Madagascar. Rapport synthétique d’activités et de
resultats TMM-PAUSENS 2013 Maladies Tropicales Negligées. Madagascar. 2013.
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contre les Maladies Endémiques et Négligées: Plan Directeur de Lutte contre les Maladies Tropicales
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51. de Silva N, Hotez PJ, Alvarado M, Basáñez M-G, Bolliger I, Bourne R, et al. The Global Burden of Dis-
ease Study 2010: Interpretation and Implications for the Neglected Tropical Diseases. PLoS Neglected
Tropical Diseases. 2014; 8(7):e2865. https://doi.org/10.1371/journal.pntd.0002865 PMID: 25058013
52. Lo NC, Bogoch II, Blackburn BG, Raso G, N’Goran EK, Coulibaly JT, et al. Comparison of community-
wide, integrated mass drug administration strategies for schistosomiasis and soil-transmitted helminthi-
asis: a cost-effectiveness modelling study. The Lancet Global Health. 2015; 3(10):e629–e38. https://
doi.org/10.1016/S2214-109X(15)00047-9 PMID: 26385302
53. Keiser J, Utzinger J. Efficacy of Current Drugs Against Soil-Transmitted Helminth Infections. Jama.
2008; 299(16). https://doi.org/10.1001/jama.299.16.1937 PMID: 18430913
54. Uneke C. Soil transmitted helminth infections and schistosomiasis in school age children in sub-Saha-
ran Africa: Efficacy of chemotherapeutic intervention since World Health Assembly Resolution 2001.
Tanzan J Health Res. 2010; 12(1):86–99. PMID: 20737834
55. Kabatereine NB, Nikolay B, Mwandawiro CS, Kihara JH, Okoyo C, Cano J, et al. Understanding Hetero-
geneity in the Impact of National Neglected Tropical Disease Control Programmes: Evidence from
School-Based Deworming in Kenya. PLOS Neglected Tropical Diseases. 2015; 9(9):e0004108. https://
doi.org/10.1371/journal.pntd.0004108 PMID: 26421808
56. Turner HC, Truscott JE, Hollingsworth TD, Bettis AA, Brooker SJ, Anderson RM. Cost and cost-effec-
tiveness of soil-transmitted helminth treatment programmes: systematic review and research needs.
Parasites & Vectors. 2015; 8(1). https://doi.org/10.1186/s13071-015-0885-3 PMID: 26137945
57. Jukes MCH, Drake LJ, Bundy DAP. School health, nutrition and education for all: levelling the playing
field. Wallingford, UK; Cambridge, MA: CABI Pub.; 2008. xii, 145 pages.
58. Makamu F, Azam M, Kazianga H. Returns to Controlling a Neglected Tropical Disease: Schistosomia-
sis Control Program and Education Outcomes in Nigeria. Economics Working Paper Series 1711 Okla-
homa State University, Department of Economics and Legal Studies in Business. 2017.
59. Welch VA, Ghogomu E, Hossain A, Awasthi S, Bhutta ZA, Cumberbatch C, et al. Mass deworming to
improve developmental health and wellbeing of children in low-income and middle-income countries: a
systematic review and network meta-analysis. The Lancet Global Health. 2017; 5(1):e40–e50. https://
doi.org/10.1016/S2214-109X(16)30242-X PMID: 27955788
60. Croke K, Hicks JH, Hsu E, Kremer M, Miguel E. Should the WHO withdraw support for mass deworm-
ing? PLOS Neglected Tropical Diseases. 2017; 11(6):e0005481. https://doi.org/10.1371/journal.pntd.
0005481 PMID: 28594928
61. Taylor-Robinson DC, Maayan N, Soares-Weiser K, Donegan S, Garner P. Deworming drugs for soil-
transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school perfor-
mance. Cochrane Database Syst Rev. 2012. https://doi.org/10.1002/14651858.CD000371.pub4 PMID:
22786473
62. Ahuja A, Baird S, Hicks JH, Kremer M, Miguel E, Powers S. When Should Governments Subsidize
Health? The Case of Mass Deworming. The World Bank Economic Review. 2015; 29(suppl 1):S9–S24.
https://doi.org/10.1093/wber/lhv008
Health, financial, and education gains of NTD control in Madagascar
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007002 December 27, 2018 16 / 17
63. Brooker S, King CH, Bertino A-M. Asymmetries of Poverty: Why Global Burden of Disease Valuations
Underestimate the Burden of Neglected Tropical Diseases. PLoS Neglected Tropical Diseases. 2008; 2
(3):e209. https://doi.org/10.1371/journal.pntd.0000209 PMID: 18365036
64. Garcia HH, Hall A, Horton S, de Silva N. The Costs and Cost-Effectiveness of Mass Treatment for Intes-
tinal Nematode Worm Infections Using Different Treatment Thresholds. PLoS Neglected Tropical Dis-
eases. 2009; 3(3):e402. https://doi.org/10.1371/journal.pntd.0000402 PMID: 19333371
65. King CH. Health metrics for helminth infections. Acta Tropica. 2015; 141:150–60. https://doi.org/10.
1016/j.actatropica.2013.12.001 PMID: 24333545
66. Moser W, Schindler C, Keiser J. Efficacy of recommended drugs against soil transmitted helminths:
systematic review and network meta-analysis. Bmj. 2017:j4307. https://doi.org/10.1136/bmj.j4307
PMID: 28947636
Health, financial, and education gains of NTD control in Madagascar
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007002 December 27, 2018 17 / 17
